New Onset of Severe Allergic Manifestations in Long Term Survivors After Cord Blood Transplantation  by Vaughan, L.A. et al.
Table. Characteristics of Patients Who Developed VTE after Allotransplant: Early VS Late
Early VTE (#6 mo) Late VTE (>6 mo)
p-valueN 5 22 (%) N 5 13 (%)
Gender (M/F) 17/5 6/7 0.06
Median age at allotransplant, years (range) 56 (20-63) 55 (38-64) 0.88
Diagnosis required allotransplant 0.31
Acute Leukemia 13 (60%) 6 (46%)
Myelodysplastic Syndrome 4 (18%) 0 (0%)
Myeloproliferative Neoplasm 1 (4%) 3 (23%)
Non Hodgkin Lymphoma 2 (9%) 2 (15%)
Chronic Lymphocytic Leukemia 2 (9%) 1 (8%)
Multiple Myeloma 0 (0%) 1 (8%)
Past history of VTE prior to allotransplant 5 (23%) 4 (31%) 0.60
History of tobacco smoking 10 (46%) 6 (46%) 0.97
Atherosclerotic risk factors* 7 (32%) 4 (31%) 0.94
Conditioning regimen 0.15
Myeloablative 17 (77%) 7 (54%)
Reduced Intensity 5 (23%) 6 (46%)
Stem Cell source 0.62
Bone marrow 5 (23%) 2 (15%)
Peripheral blood 16 (73%) 11 (85%)
Cord blood 1 (4%) 0 (0%)
HCT-CI† 0.09
0 2 (9%) 3 (23%)
1-2 9 (41%) 1 (8%)
$3 11 (50%) 9 (69%)
ECOG Performance status at VTE diagnosis 0.12
0-2 13 (59%) 11 (85%)
3-4 9 (41%) 2 (15%)
Pharmacologic VTE prophylaxis 1 (4%) 0 (0%) 0.44
Time from allotransplant to VTE, days (range) 98 (-3 to 174) 393 (208 to 1853) <0.0001
Active hematologic malignancy at VTE 2 (9%) 4 (31%) 0.10
Active graft versus host disease ($grade3) 10 (46%) 8 (62%) 0.36
Central venous catheter related VTE 15 (68%) 1 (8%) 0.001
Median platelet count (x106/mm3) (range) 54 (5-193) 95 (26-676) 0.031
*Atherosclerotic risk factors - obesity (body mass index > 30%), hypertension, dyslipidemia, diabetes mellitus.
†Hematopoietic Cell Transplantation-Comorbidity Index.
Poster Session I S285duration was 53 days (range, 6-877 d). The reasons of treatment
discontinuation included complete clinical response (32%), clini-
cally significant bleeding (32%), progressive thrombocytopenia
(24%) or others (12%). Six patients (17%) subsequently developed
recurrent VTE and one of these occurred during anticoagulation.
Conclusion: VTE may be a more frequent complication of allo-
transplant than previously recognized. Treatment of VTE following
allotransplant is challenging due to patients’ complexity and poten-
tial complications. Prospective studies are warranted to establish the
appropriate strategies for prevention and management.221
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Background:Umbilical-cord-blood-transplantation (CBT) is an ef-
fective treatment for benign and malignant diseases. Late effects of
CBT are not well described in the literature. In this study, we present
our experience with new onset allergies after CBT.
Methods: After the first patient experienced new onset severe al-
lergy related to peanut exposure, all CBT patients at a single cen-
ter were prospectively followed for new allergy development.
Presence of allergy was defined as a positive skin test or by radio-
allergosorbent test (RAST). Symptomatic allergy requiring imme-diate attention with clinical manifestations also defined as allergic
disease.
Results: Fifty patients received CBT between March 2006 and
June 2011. The majority of patients (n 5 43) received CBT for
hematological malignancies. The median follow-up after CBT
was 445 days (range, 12-2022). Twenty eight (56%) patients un-
derwent myeloablative and 22 (44%) received reduced-intensity
conditioning regimen CBT. Acute GVHD (grade III-IV) occurred
in 14 (28%) and chronic GVHD occurred in 14 of 41 patients
(34%) surviving beyond 100 days. At the time of analysis, 30 pa-
tients were alive with 3 year actuarial survival of 55.5%; median
follow-up of surviving patients was 910 days (range, 68-2022).
The allergic syndrome developed in 5 patients, with Kaplan-Meier
cumulative probability of 18.467.6%. The median time to onset
of new allergy presentation after transplantation was 298 days
(range, 250 to 809). Severity and types of allergies described in
Table 1. Among 6 patients (2 with allergies), trends were seen
between tissue-homing Treg subsets at engraftment and the de-
velopment of peanut allergies with allergic individuals character-
ized by decreased CLA+ (skin-homing) Tregs (median, 3.22% vs.
1.12%; P 5 0.064) and increased a4b7+ (gut-homing) Tregs
(median, 22.0% vs. 41.0%; P 5 0.064) (no allergy vs. allergy,
respectively).
Conclusion: This observation is important as it has therapeutic im-
plications in long term survivors after CBT. Allergy development has
been linked to a delayed maturation of the immune system in several
different studies. Th2-biased immune reconstitution after CBT
could be the mechanism for allergy transfer via cytokines induced
IgE synthesis. Impairment of regulatory T-cells after CBT is be-
lieved to be also one contributing factor in allergic disease. Counsel-
ing of patients to this previously unknown complication of CBT is
recommended.
